This website is intended for UK healthcare professionals only Log in | Register

Editorial articles

November 2004 Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 77–AIC 79

The potential role for recombinant factor VIIa in cardiac surgery

Paul Diprose, Ravi Gill

Abstract

Recombinant factor VIIa (rFVIIa, Novoseven®, Novo
Nordisk®, Denmark) is established for the management
of bleeding episodes in haemophiliac patients with inhibitors.
Interest has been growing in the use of this drug
for the management of severe intractable bleeding following
major trauma and surgery.

| Full text

September 2004 Br J Cardiol 2004;11:347-9

Fashioning a new approach to heart disease in women

Vahini V Naidoo

Abstract

Implementation of new evidence-based guidelines is one of
the most daunting tasks facing healthcare professionals
today, and in order to meet this challenge we need to be
well informed and to inform our patients.

| Full text

September 2004 Br J Cardiol 2004;11:343-5

Low haemoglobin in patients with chronic heart failure: common but commonly ignored

Paul R Kalra

Abstract

Although studies from two decades ago documented
the association of low haemoglobin with chronic
heart failure (CHF), the potential for an important
pathophysiological link has largely been ignored until recently.
In 2000 Silverberg and colleagues reported on a cohort of
patients (n=142) attending a specialist nephro-cardiology clinic.
1 Anaemia (haemoglobin < 12 g/dL) was present in over half the patients and was associated with symptom severity.

| Full text

September 2004 Br J Cardiol 2004;11:339-41

NICE try but a long way to go in heart failure

Andrew Owen

Abstract

The pharmacological treatment of patients with chronic
heart failure has changed dramatically over the past 25
years. This change began with the demonstration of
the beneficial effects of the combination of hydralazine and
isosorbide dinitrate in the V-HeFT-I (Veterans Administration
Co-operative Study) trial.

| Full text

July 2004 Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 35–AIC 37

Follow-on angioplasty via the radial artery – a personal view

Nicholas MK Robinson

Abstract

The benefits of transradial coronary intervention (TRI)
over transfemoral (TFI) are becoming increasingly
recognised. In the United Kingdom, an increasing
number of interventions are being performed by the radial
approach and courses supporting this approach are now well
developed.

| Full text

July 2004 Br J Cardiol (Acute Interv Cardiol) 2004;11:AIC 38–AIC 40

Statin therapy following percutaneous coronary revascularisation: time to make LIPS stick?

Arun Natarajan, Scott A Gall, Azfar Zaman

Abstract

The success of the 3-hydroxy-3-methylglutaryl-coenzyme
A reductase inhibitors (statins) in ameliorating
atherothrombotic events is firmly established. Large
randomised controlled clinical trials have consistently (and
unequivocally) demonstrated a beneficial role in reducing
coronary events and total mortality in patients with advanced
coronary artery disease (CAD).

| Full text

July 2004 Br J Cardiol 2004;11:261-2

Living with an ICD – the price of saving a life

Violet R Henry, Sharon Smart, Salma Akram, Katherine McGrath, Ian Wright, Sophie Blackman, Nicholas S Peters

Abstract

Most treatments administered to patients act to relieve symptoms. But in the name of saving life,
having an implanted cardioverter defibrillator (ICD) leaves the patient prone to unpredictable episodes of
symptoms including collapse, and abrupt and explosive chest pain, of which the informed patient may live in
persistent fear.

| Full text

May 2004 Br J Cardiol 2004;11:175-8

General practitioners with a special interest

David Fitzmaurice

Abstract

Despite many attempts at reform, there has been a persistent
shortfall in the number of consultant cardiologists.
As long ago as 1985, the conservative recommendation
was made that each general hospital should have
at least one physician, practising general medicine but
having a special expertise and training in cardiology.

| Full text

March 2004 Br J Cardiol 2004;11:93

OTC statins – an ethical test case

Peter Stott

Abstract

Statins are currently provided at NHS expense for patients
with coronary heart disease (CHD), diabetes and those
whose coronary risk is greater than 3% per year.

| Full text

March 2004 Br J Cardiol 2004;11:89-91

OTC statins: the implications for primary prevention in the UK

Rubin Minhas

Abstract

The difficulty in delivering a viable primary prevention
policy has been evident ever since the publication of
the National Service Framework for Coronary Heart
Disease (NSF-CHD).

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now